Ipsen expands early development pipeline with Simcere Zaiming’s innovative antibody drug conjugate
PARIS, FRANCE; 22 DECEMBER 2025 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today an exclusive licensing agreement for global rights outside of Greater China, for SIM0613, an antibody-drug conjugate (ADC) with best-in-class potential. Targeting the LRRC15 protein, SIM0613 is designed for enhanced tumor penetration and differentiated anti-tumor activity in solid tumors with the highest unmet needs. Read More
Recent Posts
Romanian Inflation Ends Tumultuous Year in Politics Close to 10%
UK Boosts Support For Offshore Wind in Bumper Auction
Ireland Is Trying to Get Back on the Data Center Bandwagon
Notice Concerning Change of Representative Executive Officer
Polish Recycler Bets Millions on Europe’s Critical Metals Push
Blistering Metals Rally Sends Silver, Tin and Copper to Records
Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities
TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale
New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS
TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics
